Gold rose above $4,500 an ounce for the first time on Wednesday as escalating tensions in Venezuela and expectations for more US rate cuts continue to lift demand for the safe-haven metal. Spot gold ...

Kronos Worldwide, Inc. KRO reported a third-quarter 2025 net loss of $37 million or 32 cents per share. This compares unfavorably to profits of $71.8 million, or 62 cents per share in the year-ago ...

Getting your Trinity Audio player ready... For what it’s worth, the Beatles stayed together for about a decade. The Kronos Quartet, a boundary-pushing string ensemble, has lasted more than five times ...

Kronos is a HOLD: TiO2 demand should rise, but KRO lacks operating leverage and control over key feedstocks to benefit from upside. KRO faces significant competition from Chinese producers, especially ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. Tang Capital Partners’ Concentra inked a definitive deal to acquire Kronos’ ...

(RTTNews) - Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common ...

Performances in N.Y.C. Advertisement Supported by The venerable quartet returned to Zankel Hall with a typically eclectic program and a newfound emotional intensity. By Corinna da Fonseca-Wollheim The ...

Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...

Kronos Q324 sales volumes soared, offsetting flat TiO2 selling prices to deliver +22% YoY revenue growth along with improved profitability. The company faces high growth expectations as it integrates ...

(RTTNews) - Kronos Bio, Inc. (KRON) announced on Wednesday that it has appointed CFO and COO Deborah Knobelman as president and interim chief executive officer, with effect from December 3. In ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.